CMP Therapeutics Ltd.
This article was originally published in Start Up
Executive Summary
Chitin may be the second most common molecule on earth. It could be the source of a treatment for the common cold, too. So hope investors in CMP Therapeutics Ltd., which is developing a micronized nose-spray version of the polysaccharide chitin. The company is also using chitin as the basis for programs in novel allergy and asthma therapies, vaccine adjuvants, and nutritional products.